Apimeds Pharmaceuticals US (APUS) Enterprise Value (2023 - 2025)

Apimeds Pharmaceuticals US's Enterprise Value history runs 3 years deep, the most recent figure standing at -$9.6 million for Q4 2025.

• Quarterly Enterprise Value fell 278819.1% year-over-year to -$9.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$9.6 million (down 278819.1% YoY) and the FY2025 annual result came in at -$9.6 million, down 278819.1% from the prior year.
• Enterprise Value was -$9.6 million for Q4 2025 at Apimeds Pharmaceuticals US, down from -$7.0 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$3455.0 in Q4 2024 and bottomed at -$9.6 million in Q4 2025.
• A 3-year average of -$4.3 million and a median of -$3.7 million in 2023 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2024 — Enterprise Value soared 99.16% — and 2025, when it tumbled 278819.1%.
• Apimeds Pharmaceuticals US's Enterprise Value stood at -$410481.0 in 2023, then surged by 99.16% to -$3455.0 in 2024, then tumbled by 278819.1% to -$9.6 million in 2025.
• Business Quant data shows APUS's Enterprise Value at -$9.6 million in Q4 2025, -$7.0 million in Q3 2025, and -$8.7 million in Q2 2025.